Activity of Pembrolizumab in Recurrent Cervical Cancer: Case Series and Review of Published Data
Conclusions
Pembrolizumab shows promising activity in heavily pretreated patients with recurrent cervical cancer in a real-life clinical setting. Treatment was generally well tolerated, and adverse effects were manageable. Growing evidence supports the use of pembrolizumab in this group of patients.
Source: International Journal of Gynecological Cancer - Category: Cancer & Oncology Tags: Cervical Cancer Source Type: research
More News: Academia | Cancer | Cancer & Oncology | Cervical Cancer | CT Scan | Statistics | Study | Toxicology